SML4094

RECTAS

≥98% (HPLC)

• Synonym(e): 2-Chloro-6-Furfurylaminopurine, 2-Chloro-N-(2-furanylmethyl)-7H-purin-6-amine, 2-Chloro-N-(2-furanylmethyl)-9H-purin-6-amine, 2-Chloro-N-[(furan-2-yl)methyl]-7H-purin-6-amine, 2-Chloro-N6-furfuryl-adenine, NSC 45794, NSC-45794, NSC45794
• Empirische Formel (Hill-System): C₁₀H₈ClN₅O
• CAS-Nummer: 101862-47-9
• Molekulargewicht: 249.66
• MDL-Nummer: MFCD09792860
• UNSPSC-Code: 12352200

Eigenschaften

• Qualitätsniveau: 100
• Assay: ≥98% (HPLC)
• Form: powder
• Farbe: white to beige
• Löslichkeit: DMSO: 2 mg/mL, clear (Warmed)
• Lagertemp.: -10 to -25°C
• SMILES String: Clc1nc2[nH]cnc2c(n1)NCc3[o]ccc3
• InChI: 1S/C10H8ClN5O/c11-10-15-8(7-9(16-10)14-5-13-7)12-4-6-2-1-3-17-6/h1-3,5H,4H2,(H2,12,13,14,15,16)
• InChIKey: QGUOPVCOXHVPJX-UHFFFAOYSA-N

Beschreibung

Biochem./physiol. Wirkung

Orally active, CDC2-like kinase 1 (CLK1) allosteric activator that enhances promotes CLK1/SRSF5 pathway-mediated pre-mRNA splicing events.
RECTAS is an orally active, CDC2-like kinase 1 (CLK1) allosteric activator that enhances SRSF6 c-terminal RS domain phosphorylation by CLK1, thereby promoting CLK1/SRSF5 pathway-mediated pre-mRNA splicing events. RECTAS restores IKBKAP-familial dysautonomia (FD) exon 20 inclusion in cultured cells (2-10 μM; FD patient iPSC-SNs & murine neuro 2A cells) and in IKBKAP-FD transgenic mice in vivo (two p.o. doses of 300 or 400 mg/kg 4h apart). RECTAS suppresses MC38 tumor growth (by 37/47% at 10/25 μM at the end of 33-day treatment via daily intratumoral injection) by reducing aberrant splicing events and enhancing the splice-neoantigens production.

Sicherheitshinweise

• Piktogramme: GHS06
• Signalwort: Danger
• H-Sätze: H301
• P-Sätze: P264 - P270 - P301 + P310 - P405 - P501
• Gefahreneinstufungen: Acute Tox. 3 Oral
• Lagerklassenschlüssel: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• WGK: WGK 3
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable